Compare GPRE & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | AURA |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 713.4M |
| IPO Year | 2004 | 2021 |
| Metric | GPRE | AURA |
|---|---|---|
| Price | $16.57 | $7.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $12.57 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.2M | 565.4K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,091,680,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | $40.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $4.73 |
| 52 Week High | $19.65 | $9.54 |
| Indicator | GPRE | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 53.80 |
| Support Level | $14.01 | $7.13 |
| Resistance Level | $19.29 | $7.83 |
| Average True Range (ATR) | 0.93 | 0.34 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 19.95 | 75.61 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.